

PCV13 doses received among participants in the carriage and otitis media samples.

	Bedouin children					Jewish children				
	0-1m	2-3m	4-11m	12-23m	24-35m	0-1m	2-3m	4-11m	12-23m	24-35m
Carriage sample¹	N = 86	N = 70	N = 234	N = 184	N = 111	N = 33	N = 51	N = 168	N = 205	N = 96
0 doses	86 (100)	25 (35.7)	9 (3.8)	4 (2.2)	1 (0.9)	33 (100)	10 (19.6)	4 (2.4)	4 (1.8)	2 (2.1)
1 dose	0	45 (64.3)	44 (18.8)	7 (3.8)	2 (1.8)	0	41 (80.4)	16 (9.5)	3 (1.4)	0
2 doses	0	0	180 (76.9)	32 (17.4)	10 (9.0)	0	0	148 (88.1)	52 (24.0)	6 (6.2)
3 doses	0	0	1 (0.4)	140 (76.1)	96 (86.5)	0	0	0	157 (72.4)	88 (91.7)
4 doses	0	0	0	1 (0.5)	2 (1.8)	0	0	0	1 (0.5)	0
Otitis media sample¹	N = 16	N = 22	N = 105	N = 101	N = 43	N = 17	N = 16	N = 189	N = 272	N = 72
0 doses	16 (100)	11 (50.0)	4 (3.8)	2 (2.0)	0	17 (100)	5 (31.2)	5 (2.6)	10 (3.7)	1 (1.4)
1 dose	0	11 (50.0)	16 (15.2)	2 (2.0)	1 (2.3)	0	11 (68.8)	11 (5.8)	6 (2.2)	4 (5.6)
2 doses	0	0	84 (80.0)	18 (17.8)	3 (7.0)	0	0	168 (88.9)	79 (29.0)	5 (6.9)
3 doses	0	0	1 (1.0)	79 (78.2)	35 (81.4)	0	0	5 (2.6)	176 (64.7)	62 (86.1)
4 doses	0	0	0	0	4 (9.3)	0	0	0 (0)	1 (0.4)	0

¹Israel has a two-dose-plus-booster schedule with a primary series around ages 2 and 4 months and booster dose around 12 months. PCV13 was in routine use for all doses among children included in the samples.